Investing.com -- Evercore ISI downgraded Match Group Inc (NASDAQ:MTCH) to "In Line" from "Outperform," citing a weak first-quarter outlook and uncertainty surrounding its leadership transition ...

Good morning, and welcome to the Evercore Fourth Quarter 2024 and Full-Year Earnings Conference Call. Today's call is scheduled to last about 1 hour, including remarks by Evercore management and ...

Evercore ISI upgraded CarMax (KMX) to Outperform from In Line with a price target of $110, up from $90. The firm sees the company’s improving comp and share trends persisting amid a favorable ...

Fourth Quarter and Full Year Net Revenues were $975.3 million and $3.0 billion, respectively, on a U.S. GAAP basis and $980.5 million and $3.0 billion, respectively, on an Adjusted basis ...

(RTTNews) - Evercore Inc. (EVR) reported a profit for its fourth quarter that increased from last year and beat the Street estimates. The company's earnings came in at $140.44 million, or $3.30 ...

Investing.com -- Evercore ISI lifted Juniper Networks (NYSE:JNPR) stock to Outperform from In-Line on Tuesday while maintaining a $40 price target. Juniper shares rose nearly 2% after the market open.

In a report released yesterday, Michael Binetti from Evercore ISI maintained a Hold rating on VF (VFC – Research Report), with a price target of $27.00. The company’s shares closed yesterday ...

U.S. President Donald Trump's tariffs on Canada, Mexico and China have the potential to impact corporate profits, as well as to dictate the path of inflation, economic growth and stock market ...

Evercore ISI analyst David Palmer maintained a Buy rating on Mondelez International (MDLZ – Research Report) yesterday and set a price target of $67.00. The company’s shares closed yesterday ...

Evercore ISI upgraded Marriott International (MAR, Financials) to Outperform from In-Line, citing robust travel demand, the company's brand strength, and its Bonvoy loyalty program's network effect.

Evercore ISI analyst Liisa Bayko maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) on January 31 and set a price target of $515.00. The company’s shares closed last ...